Evidence map›Paper›PMID 36403362›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2022

In vivo efficiency of praziquantel treatment of single-sex Schistosoma japonicum aged three months old in mice.

Ning Wang, Han-Qi Peng, Chang-Zhe Gao, Yu-Heng Cheng, Meng-Tao Sun, Guo-Li Qu, Joanne P Webster, Da-Bing Lu

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Single-sex schistosomiasis: a mini review.Frontiers in immunology · 2023
    Review
  7. Frontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ning WangDepartment of Epidemiology and Statistics, School of Public Health, Soochow University, Suzhou, China.
Han-Qi PengDepartment of Epidemiology and Statistics, School of Public Health, Soochow University, Suzhou, China.
Chang-Zhe GaoDepartment of Epidemiology and Statistics, School of Public Health, Soochow University, Suzhou, China.
Yu-Heng ChengDepartment of Epidemiology and Statistics, School of Public Health, Soochow University, Suzhou, China.
Meng-Tao SunDepartment of Epidemiology and Statistics, School of Public Health, Soochow University, Suzhou, China.
Guo-Li QuKey Laboratory of National Health and Family Planning Commission on Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, China.
Joanne P WebsterCentre for Emerging, Endemic and Exotic Diseases (CEEED), Department of Pathology and Population Sciences, Royal Veterinary College, University of London, London, United Kingdom. Electronic address: jowebster@rvc.ac.uk.
Da-Bing LuDepartment of Epidemiology and Statistics, School of Public Health, Soochow University, Suzhou, China. Electronic address: Ludabing@suda.edu.cn.
Soochow University · CNNational Health and Family Planning Commission · CNRoyal Veterinary College · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schistosomiasis is a major neglected tropical disease mainly caused by Schistosoma haematobium, S. japonicum and S. mansoni, and results in the greatest disease burden. Mass drug administration (MDA) with praziquantel (PZQ), a single drug only available for the disease, has played a vital role in schistosomiasis control. Therefore, any possibility of selection of the parasites for PZQ resistance or low sensitivity may hamper the 2030's target of global disease elimination. We had experimentally demonstrated the long-term survival and reproductive potential of single-sex (of either sex) S. japonicum infections in definitive hosts mice. What has not yet been adequately addressed is whether the long live single-sex schistosomes remain sensitive to PZQ, and what reproduction potential for those schistosomes surviving treatment may have. We therefore performed experimental mice studies to explore the treatment effectiveness of PZQ (at total doses of 200 or 400 mg/kg, corresponding to the sub-standard or standard treatment doses in humans) for single-sex S. japonicum aged three months old. The results showed that no treatment efficiency was observed on female schistosomes, whereas on male schistosomes only at PZQ 400 mg/kg a significant higher efficiency in reducing worm burdens was observed. Moreover, either schistosome males or females surviving PZQ treatment remained their reproduction potential as normal. The results indicate that long (i.e., three months) live single-sex S. japonicum can easily survive the current treatment strategy, and moreover, any schistosomes, if with PZQ resistance or low sensitivity, could be easily transmitted in nature. Therefore, in order to realize the target for the national and the global schistosomiasis elimination, there is undoubtedly a great need for refining PZQ administration and dosage, looking for alternative therapies, and/or developing vaccines against schistosome.

Indexed as

Schistosoma japonicumSchistosomiasis mansoniAnimalsFemaleHumansInfantMaleMicePraziquantelSchistosoma haematobiumSchistosoma mansoniTreatment OutcomePraziquantelPraziquantelSingle-sex infectionS. japonicumTreatment efficiency

Identifiers

PMID36403362
PMCPMC9771832
OpenAlexW4309047029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.